Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

INTRODUCTION: In clinical trials of alemtuzumab, autoimmune thyroid adverse events (AEs) were frequent. Here, we assess the impact of thyroid AEs on health-related quality of life (HRQL) in alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: In phase 3 CARE-MS I...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertolotto, Antonio, Arroyo, Rafael, Celius, Elisabeth G., Comi, Giancarlo, Havrdova, Eva Kubala, Honeycutt, William David, Hunter, Samuel F., Izquierdo, Guillermo, Kornek, Barbara, Miller, Tamara, Mitsikostas, Dimos D., Singer, Barry A., Ziemssen, Tjalf, Chung, Luke, Daizadeh, Nadia, Afsar, Salman, Hashemi, Lobat, Senior, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606412/
https://www.ncbi.nlm.nih.gov/pubmed/32410147
http://dx.doi.org/10.1007/s40120-020-00191-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606412/
https://www.ncbi.nlm.nih.gov/pubmed/32410147
http://dx.doi.org/10.1007/s40120-020-00191-7

Ejemplares similares